{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:33:50Z","timestamp":1794893630827,"version":"4.9.1"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017R1A2B4011780"],"award-info":[{"award-number":["NRF-2017R1A2B4011780"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2017M3A9A7050803"],"award-info":[{"award-number":["NRF-2017M3A9A7050803"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1A5A2945889"],"award-info":[{"award-number":["NRF-2016R1A5A2945889"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tumor cell-intrinsic mechanisms and complex interactions with the tumor microenvironment contribute to therapeutic failure via tumor evolution. It may be possible to overcome treatment resistance by developing a personalized approach against relapsing cancers based on a comprehensive analysis of cell type-specific transcriptomic changes over the clinical course of the disease using single-cell RNA sequencing (scRNA-seq).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Here, we used scRNA-seq to depict the tumor landscape of a single case of chemo-resistant metastatic, muscle-invasive urothelial bladder cancer (MIUBC) addicted to an activating Harvey rat sarcoma viral oncogene homolog (\n                      <jats:italic>HRAS<\/jats:italic>\n                      ) mutation. In order to analyze tumor evolution and microenvironmental changes upon treatment, we also applied scRNA-seq to the corresponding patient-derived xenograft (PDX) before and after treatment with tipifarnib, a HRAS-targeting agent under clinical evaluation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the parallel analysis of the human MIUBC and the PDX, diverse stromal and immune cell populations recapitulated the cellular composition in the human and mouse tumor microenvironment. Treatment with tipifarnib showed dramatic anticancer effects but was unable to achieve a complete response. Importantly, the comparative scRNA-seq analysis between pre- and post-tipifarnib-treated PDX revealed the nature of tipifarnib-refractory tumor cells and the tumor-supporting microenvironment. Based on the upregulation of programmed death-ligand 1 (PD-L1) in surviving tumor cells, and the accumulation of multiple immune-suppressive subsets from post-tipifarnib-treated PDX, a PD-L1 inhibitor, atezolizumab, was clinically applied; this resulted in a favorable response from the patient with acquired resistance to tipifarnib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We presented a single case report demonstrating the power of scRNA-seq for visualizing the tumor microenvironment and identifying molecular and cellular therapeutic targets in a treatment-refractory cancer patient.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13073-020-00741-6","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T05:02:48Z","timestamp":1590555768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":174,"title":["Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient"],"prefix":"10.1186","volume":"12","author":[{"given":"Hye Won","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woosung","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae-Ock","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Eun","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Areum","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joung Eun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byong Chang","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeung-Min","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4234-0380","authenticated-orcid":false,"given":"Woong-Yang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"key":"741_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/ng.3806","volume":"49","author":"JK Lee","year":"2017","unstructured":"Lee JK, Wang J, Sa JK, Ladewig E, Lee HO, Lee IH, Kang HJ, Rosenbloom DS, Camara PG, Liu Z, et al. Spatiotemporal genomic architecture informs precision oncology in glioblastoma. Nat Genet. 2017;49:594\u20139.","journal-title":"Nat Genet"},{"key":"741_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/omi.2017.0174","volume":"22","author":"K Dzobo","year":"2018","unstructured":"Dzobo K, Senthebane DA, Thomford NE, Rowe A, Dandara C, Parker MI. Not everyone fits the mold: intratumor and intertumor heterogeneity and innovative cancer drug design and development. OMICS. 2018;22:17\u201334.","journal-title":"OMICS"},{"key":"741_CR3","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.14694\/EDBK_158808","volume":"35","author":"CM Lovly","year":"2016","unstructured":"Lovly CM, Salama AK, Salgia R. Tumor heterogeneity and therapeutic resistance. Am Soc Clin Oncol Educ Book. 2016;35:e585\u201393.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"741_CR4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/ng.3590","volume":"48","author":"J Wang","year":"2016","unstructured":"Wang J, Cazzato E, Ladewig E, Frattini V, Rosenbloom DI, Zairis S, Abate F, Liu Z, Elliott O, Shin YJ, et al. Clonal evolution of glioblastoma under therapy. Nat Genet. 2016;48:768\u201376.","journal-title":"Nat Genet"},{"key":"741_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","volume":"501","author":"MR Junttila","year":"2013","unstructured":"Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346\u201354.","journal-title":"Nature"},{"key":"741_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350.","journal-title":"Nat Med"},{"key":"741_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2016.01.043","volume":"387","author":"T Wu","year":"2017","unstructured":"Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61\u20138.","journal-title":"Cancer Lett"},{"key":"741_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ccell.2017.06.003","volume":"32","author":"Q Wang","year":"2017","unstructured":"Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, de Carvalho AC, Lyu S, Li P, Li Y, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 2017;32:42\u201356 e46.","journal-title":"Cancer Cell"},{"key":"741_CR9","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1111\/febs.13705","volume":"283","author":"F Caiado","year":"2016","unstructured":"Caiado F, Silva-Santos B, Norell H. Intra-tumour heterogeneity - going beyond genetics. FEBS J. 2016;283:2245\u201358.","journal-title":"FEBS J"},{"key":"741_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13059-015-0692-3","volume":"16","author":"KT Kim","year":"2015","unstructured":"Kim KT, Lee HW, Lee HO, Kim SC, Seo YJ, Chung W, Eum HH, Nam DH, Kim J, Joo KM, Park WY. Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells. Genome Biol. 2015;16:127.","journal-title":"Genome Biol"},{"key":"741_CR11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13059-016-0945-9","volume":"17","author":"KT Kim","year":"2016","unstructured":"Kim KT, Lee HW, Lee HO, Song HJ, Jeong da E, Shin S, Kim H, Shin Y, Nam DH, Jeong BC, et al. Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma. Genome Biol. 2016;17:80.","journal-title":"Genome Biol"},{"key":"741_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.5483\/BMBRep.2017.50.6.086","volume":"50","author":"HO Lee","year":"2017","unstructured":"Lee HO, Park WY. Single-cell RNA-Seq unveils tumor microenvironment. BMB Rep. 2017;50:283\u20134.","journal-title":"BMB Rep"},{"issue":"408","key":"741_CR13","doi-asserted-by":"publisher","first-page":"eaan4730","DOI":"10.1126\/scitranslmed.aan4730","volume":"9","author":"Alex K. Shalek","year":"2017","unstructured":"Shalek AK, Benson M. Single-cell analyses to tailor treatments. Sci Transl Med. 2017;9(408):eaan4730. https:\/\/doi.org\/10.1126\/scitranslmed.aan4730.","journal-title":"Science Translational Medicine"},{"key":"741_CR14","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.celrep.2018.10.047","volume":"25","author":"MP Kumar","year":"2018","unstructured":"Kumar MP, Du J, Lagoudas G, Jiao Y, Sawyer A, Drummond DC, Lauffenburger DA, Raue A. Analysis of single-cell RNA-Seq identifies cell-cell communication associated with tumor characteristics. Cell Rep. 2018;25:1458\u201368 e1454.","journal-title":"Cell Rep"},{"key":"741_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13059-018-1593-z","volume":"19","author":"X Ren","year":"2018","unstructured":"Ren X, Kang B, Zhang Z. Understanding tumor ecosystems by single-cell sequencing: promises and limitations. Genome Biol. 2018;19:211.","journal-title":"Genome Biol"},{"key":"741_CR16","doi-asserted-by":"publisher","first-page":"15081","DOI":"10.1038\/ncomms15081","volume":"8","author":"W Chung","year":"2017","unstructured":"Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, Ryu HS, Kim S, Lee JE, Park YH, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun. 2017;8:15081.","journal-title":"Nat Commun"},{"key":"741_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupret","year":"2018","unstructured":"Roupret M, Babjuk M, Comperat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, BWG VR, Mostafid AH, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol. 2018;73:111\u201322.","journal-title":"Eur Urol"},{"key":"741_CR18","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","volume":"71","author":"J Alfred Witjes","year":"2017","unstructured":"Alfred Witjes J, Lebret T, Comperat EM, Cowan NC, De Santis M, Bruins HM, Hernandez V, Espinos EL, Dunn J, Rouanne M, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017;71:462\u201375.","journal-title":"Eur Urol"},{"key":"741_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.eururo.2019.03.014","volume":"75","author":"SJ Crabb","year":"2019","unstructured":"Crabb SJ. Personalised medicine for advanced urothelial cancer: what is the right way to identify the right patient for the right treatment? Eur Urol. 2019;75:965\u20136.","journal-title":"Eur Urol"},{"key":"741_CR20","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1541-7786.MCR-12-0274","volume":"10","author":"G van der Horst","year":"2012","unstructured":"van der Horst G, Bos L, van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res. 2012;10:995\u20131009.","journal-title":"Mol Cancer Res"},{"key":"741_CR21","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.3389\/fonc.2019.01270","volume":"9","author":"M Joseph","year":"2019","unstructured":"Joseph M, Enting D. Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications. Front Oncol. 2019;9:1270.","journal-title":"Front Oncol"},{"key":"741_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.bulcan.2018.07.015","volume":"105","author":"G Ma","year":"2018","unstructured":"Ma G, Yang X, Liang Y, Wang L, Li D, Chen Y, Liang Z, Wang Y, Niu H. Precision medicine and bladder cancer heterogeneity. Bull Cancer. 2018;105:925\u201331.","journal-title":"Bull Cancer"},{"key":"741_CR23","doi-asserted-by":"publisher","unstructured":"da Costa JB, Gibb EA, Nykopp TK, Mannas M, Wyatt AW, Black PC. Molecular tumor heterogeneity in muscle invasive bladder cancer: biomarkers, subtypes, and implications for therapy. Urol Oncol. 2018;S1078-1439(18)30463-0. https:\/\/doi.org\/10.1016\/j.urolonc.2018.11.015.","DOI":"10.1016\/j.urolonc.2018.11.015"},{"key":"741_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrc.2017.69","volume":"17","author":"CC Maley","year":"2017","unstructured":"Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, et al. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer. 2017;17:605\u201319.","journal-title":"Nat Rev Cancer"},{"key":"741_CR25","first-page":"69","volume":"2017","author":"DIS Rosenbloom","year":"1867","unstructured":"Rosenbloom DIS, Camara PG, Chu T, Rabadan R. Evolutionary scalpels for dissecting tumor ecosystems. Biochim Biophys Acta. 1867;2017:69\u201383.","journal-title":"Biochim Biophys Acta"},{"key":"741_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ng.3224","volume":"47","author":"C Isella","year":"2015","unstructured":"Isella C, Terrasi A, Bellomo SE, Petti C, Galatola G, Muratore A, Mellano A, Senetta R, Cassenti A, Sonetto C, et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet. 2015;47:312\u20139.","journal-title":"Nat Genet"},{"key":"741_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754\u201360.","journal-title":"Bioinformatics"},{"key":"741_CR28","doi-asserted-by":"publisher","first-page":"E2423","DOI":"10.1002\/humu.22771","volume":"36","author":"AH Ramos","year":"2015","unstructured":"Ramos AH, Lichtenstein L, Gupta M, Lawrence MS, Pugh TJ, Saksena G, Meyerson M, Getz G. Oncotator: cancer variant annotation tool. Hum Mutat. 2015;36:E2423\u20139.","journal-title":"Hum Mutat"},{"key":"741_CR29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/bioinformatics\/btr670","volume":"28","author":"V Boeva","year":"2012","unstructured":"Boeva V, Popova T, Bleakley K, Chiche P, Cappo J, Schleiermacher G, Janoueix-Lerosey I, Delattre O, Barillot E. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics. 2012;28:423\u20135.","journal-title":"Bioinformatics"},{"key":"741_CR30","volume":"5","author":"SV Puram","year":"2018","unstructured":"Puram SV, Parikh AS, Tirosh I. Single cell RNA-seq highlights a role for a partial EMT in head and neck cancer. Mol Cell Oncol. 2018;5:e1448244.","journal-title":"Mol Cell Oncol"},{"key":"741_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323.","journal-title":"BMC Bioinformatics"},{"key":"741_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540\u201356 e525.","journal-title":"Cell"},{"issue":"4","key":"741_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/cancers10040100","volume":"10","author":"Kentaro Inamura","year":"2018","unstructured":"Inamura K. Bladder cancer: new insights into its molecular pathology. Cancers (Basel). 2018;10(4):100. https:\/\/doi.org\/10.3390\/cancers10040100.","journal-title":"Cancers"},{"key":"741_CR34","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152\u201365.","journal-title":"Cancer Cell"},{"key":"741_CR35","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1158\/1078-0432.CCR-14-1589","volume":"21","author":"HW Lee","year":"2015","unstructured":"Lee HW, Lee JI, Lee SJ, Cho HJ, Song HJ, Jeong DE, Seo YJ, Shin S, Joung JG, Kwon YJ, et al. Patient-derived xenografts from non-small cell lung cancer brain metastases are valuable translational platforms for the development of personalized targeted therapy. Clin Cancer Res. 2015;21:1172\u201382.","journal-title":"Clin Cancer Res"},{"key":"741_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15\u201321.","journal-title":"Bioinformatics"},{"key":"741_CR37","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.cell.2015.05.002","volume":"161","author":"EZ Macosko","year":"2015","unstructured":"Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, Tirosh I, Bialas AR, Kamitaki N, Martersteck EM, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell. 2015;161:1202\u201314.","journal-title":"Cell"},{"key":"741_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189\u201396.","journal-title":"Science"},{"key":"741_CR39","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1038\/ncomms8866","volume":"6","author":"JA Ramilowski","year":"2015","unstructured":"Ramilowski JA, Goldberg T, Harshbarger J, Kloppmann E, Lizio M, Satagopam VP, Itoh M, Kawaji H, Carninci P, Rost B, Forrest AR. A draft network of ligand-receptor-mediated multicellular signalling in human. Nat Commun. 2015;6:7866.","journal-title":"Nat Commun"},{"key":"741_CR40","first-page":"1695","volume":"1695","author":"G Cs\u00e1rdi","year":"2006","unstructured":"Cs\u00e1rdi G, Nepusz T. The igraph software package for complex network research. InterJournal Complex Syst. 2006;1695:1695.","journal-title":"InterJournal Complex Syst"},{"key":"741_CR41","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1093\/bioinformatics\/btu393","volume":"30","author":"Z Gu","year":"2014","unstructured":"Gu Z, Gu L, Eils R, Schlesner M, Brors B. circlize implements and enhances circular visualization in R. Bioinformatics. 2014;30:2811\u20132.","journal-title":"Bioinformatics"},{"key":"741_CR42","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/S1470-2045(10)70086-3","volume":"11","author":"G Sonpavde","year":"2010","unstructured":"Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010;11:861\u201370.","journal-title":"Lancet Oncol"},{"key":"741_CR43","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.juro.2015.06.115","volume":"195","author":"C Oing","year":"2016","unstructured":"Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C. Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond-a comprehensive review of the current literature. J Urol. 2016;195:254\u201363.","journal-title":"J Urol"},{"key":"741_CR44","doi-asserted-by":"publisher","unstructured":"Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, et al. OncoKB: a precision oncology knowledge base. JCO Precis Oncol. 2017. https:\/\/doi.org\/10.1200\/PO.17.00011.","DOI":"10.1200\/PO.17.00011"},{"key":"741_CR45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013821","volume":"5","author":"LC Kompier","year":"2010","unstructured":"Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5:e13821.","journal-title":"PLoS One"},{"key":"741_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJM199203123261104","volume":"326","author":"D Sidransky","year":"1992","unstructured":"Sidransky D, Frost P, Von Eschenbach A, Oyasu R, Preisinger AC, Vogelstein B. Clonal origin of bladder cancer. N Engl J Med. 1992;326:737\u201340.","journal-title":"N Engl J Med"},{"key":"741_CR47","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1634\/theoncologist.10-8-565","volume":"10","author":"NM Appels","year":"2005","unstructured":"Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist. 2005;10:565\u201378.","journal-title":"Oncologist"},{"key":"741_CR48","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1039\/C7MD00030H","volume":"8","author":"J Wang","year":"2017","unstructured":"Wang J, Yao X, Huang J. New tricks for human farnesyltransferase inhibitor: cancer and beyond. Medchemcomm. 2017;8:841\u201354.","journal-title":"Medchemcomm"},{"key":"741_CR49","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1158\/1535-7163.MCT-05-0398","volume":"5","author":"RA Lubet","year":"2006","unstructured":"Lubet RA, Christov K, You M, Yao R, Steele VE, End DW, Juliana MM, Grubbs CJ. Effects of the farnesyl transferase inhibitor R115777 (Zarnestra) on mammary carcinogenesis: prevention, therapy, and role of HaRas mutations. Mol Cancer Ther. 2006;5:1073\u20138.","journal-title":"Mol Cancer Ther"},{"key":"741_CR50","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrc3793","volume":"14","author":"MS Sosa","year":"2014","unstructured":"Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14:611\u201322.","journal-title":"Nat Rev Cancer"},{"key":"741_CR51","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.juro.2007.03.007","volume":"178","author":"T Nomura","year":"2007","unstructured":"Nomura T, Huang WC, Seo S, Zhau HE, Mimata H, Chung LW. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma. J Urol. 2007;178:292\u2013300.","journal-title":"J Urol"},{"key":"741_CR52","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/18715206113139990092","volume":"14","author":"T Nomura","year":"2014","unstructured":"Nomura T, Huang WC, Zhau HE, Josson S, Mimata H, Chung LW. beta2-microglobulin-mediated signaling as a target for cancer therapy. Anti Cancer Agents Med Chem. 2014;14:343\u201352.","journal-title":"Anti Cancer Agents Med Chem"},{"key":"741_CR53","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1016\/j.celrep.2018.03.010","volume":"22","author":"T Xie","year":"2018","unstructured":"Xie T, Wang Y, Deng N, Huang G, Taghavifar F, Geng Y, Liu N, Kulur V, Yao C, Chen P, et al. Single-cell deconvolution of fibroblast heterogeneity in mouse pulmonary fibrosis. Cell Rep. 2018;22:3625\u201340.","journal-title":"Cell Rep"},{"key":"741_CR54","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/ng.3818","volume":"49","author":"H Li","year":"2017","unstructured":"Li H, Courtois ET, Sengupta D, Tan Y, Chen KH, Goh JJL, Kong SL, Chua C, Hon LK, Tan WS, et al. Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors. Nat Genet. 2017;49:708\u201318.","journal-title":"Nat Genet"},{"key":"741_CR55","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fcell.2019.00060","volume":"7","author":"T Liu","year":"2019","unstructured":"Liu T, Zhou L, Li D, Andl T, Zhang Y. Cancer-associated fibroblasts build and secure the tumor microenvironment. Front Cell Dev Biol. 2019;7:60.","journal-title":"Front Cell Dev Biol"},{"key":"741_CR56","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","volume":"40","author":"P Pathria","year":"2019","unstructured":"Pathria P, Louis TL, Varner JA. Targeting tumor-associated macrophages in cancer. Trends Immunol. 2019;40:310\u201327.","journal-title":"Trends Immunol"},{"key":"741_CR57","doi-asserted-by":"publisher","first-page":"828","DOI":"10.3389\/fimmu.2017.00828","volume":"8","author":"G Genard","year":"2017","unstructured":"Genard G, Lucas S, Michiels C. Reprogramming of tumor-associated macrophages with anticancer therapies: radiotherapy versus chemo- and immunotherapies. Front Immunol. 2017;8:828.","journal-title":"Front Immunol"},{"key":"741_CR58","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"741_CR59","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1073\/pnas.81.3.886","volume":"81","author":"S Ikehara","year":"1984","unstructured":"Ikehara S, Pahwa RN, Fernandes G, Hansen CT, Good RA. Functional T cells in athymic nude mice. Proc Natl Acad Sci U S A. 1984;81:886\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"741_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","volume":"29","author":"A Rotte","year":"2018","unstructured":"Rotte A, Jin JY, Lemaire V. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Ann Oncol. 2018;29:71\u201383.","journal-title":"Ann Oncol"},{"key":"741_CR61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33:547\u201362.","journal-title":"Cancer Cell"},{"key":"741_CR62","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.molonc.2015.10.001","volume":"9","author":"LL Liu","year":"2015","unstructured":"Liu LL, Pfefferle A, Yi Sheng VO, Bjorklund AT, Beziat V, Goodridge JP, Malmberg KJ. Harnessing adaptive natural killer cells in cancer immunotherapy. Mol Oncol. 2015;9:1904\u201317.","journal-title":"Mol Oncol"},{"issue":"10","key":"741_CR63","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.3390\/ijms18102129","volume":"18","author":"Asma Beldi-Ferchiou","year":"2017","unstructured":"Beldi-Ferchiou A, Caillat-Zucman S. Control of NK cell activation by immune checkpoint molecules. Int J Mol Sci. 2017;18(10):2129. https:\/\/doi.org\/10.3390\/ijms18102129.","journal-title":"International Journal of Molecular Sciences"},{"key":"741_CR64","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.it.2017.06.008","volume":"38","author":"T Doebel","year":"2017","unstructured":"Doebel T, Voisin B, Nagao K. Langerhans cells - the macrophage in dendritic cell clothing. Trends Immunol. 2017;38:817\u201328.","journal-title":"Trends Immunol"},{"key":"741_CR65","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.prp.2013.11.005","volume":"210","author":"S Numakura","year":"2014","unstructured":"Numakura S, Morikawa T, Ushiku T, Toyoshima T, Fukayama M. Langerhans cell histiocytosis of the urinary bladder in a patient with bladder cancer previously treated with intravesical Bacillus Calmette-Guerin therapy. Pathol Res Pract. 2014;210:123\u20136.","journal-title":"Pathol Res Pract"},{"key":"741_CR66","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","volume":"19","author":"JJ Havel","year":"2019","unstructured":"Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133\u201350.","journal-title":"Nat Rev Cancer"},{"key":"741_CR67","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069\u201386.","journal-title":"Cancer Discov"},{"key":"741_CR68","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-018-0582-8","volume":"11","author":"JA Marin-Acevedo","year":"2018","unstructured":"Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11:39.","journal-title":"J Hematol Oncol"},{"key":"741_CR69","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50:165.","journal-title":"Exp Mol Med"},{"key":"741_CR70","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, Hackl H, Trajanoski Z. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18:248\u201362.","journal-title":"Cell Rep"},{"key":"741_CR71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ctrv.2017.12.007","volume":"64","author":"F Massari","year":"2018","unstructured":"Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev. 2018;64:11\u201320.","journal-title":"Cancer Treat Rev"},{"key":"741_CR72","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","volume":"34","author":"T Horn","year":"2016","unstructured":"Horn T, Laus J, Seitz AK, Maurer T, Schmid SC, Wolf P, Haller B, Winkler M, Retz M, Nawroth R, et al. The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol. 2016;34:181\u20137.","journal-title":"World J Urol"},{"key":"741_CR73","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH, Balmanoukian A, Loriot Y, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909\u201320.","journal-title":"Lancet"},{"key":"741_CR74","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391:748\u201357.","journal-title":"Lancet"},{"key":"741_CR75","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","volume":"25","author":"AH Nassar","year":"2019","unstructured":"Nassar AH, Umeton R, Kim J, Lundgren K, Harshman L, Van Allen EM, Preston M, Dong F, Bellmunt J, Mouw KW, et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin Cancer Res. 2019;25:2458\u201370.","journal-title":"Clin Cancer Res"},{"key":"741_CR76","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"741_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1194\/jlr.R500012-JLR200","volume":"47","author":"AD Basso","year":"2006","unstructured":"Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res. 2006;47:15\u201331.","journal-title":"J Lipid Res"},{"key":"741_CR78","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1242\/jcs.182873","volume":"129","author":"GA Hobbs","year":"2016","unstructured":"Hobbs GA, Der CJ, Rossman KL. RAS isoforms and mutations in cancer at a glance. J Cell Sci. 2016;129:1287\u201392.","journal-title":"J Cell Sci"},{"key":"741_CR79","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/abbs\/gmv090","volume":"48","author":"B Fang","year":"2016","unstructured":"Fang B. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies. Acta Biochim Biophys Sin Shanghai. 2016;48:27\u201338.","journal-title":"Acta Biochim Biophys Sin Shanghai"},{"key":"741_CR80","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature13121","volume":"508","author":"C Sun","year":"2014","unstructured":"Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508:118\u201322.","journal-title":"Nature"},{"key":"741_CR81","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.12688\/f1000research.12174.1","volume":"6","author":"L Vera-Ramirez","year":"2017","unstructured":"Vera-Ramirez L, Hunter KW. Tumor cell dormancy as an adaptive cell stress response mechanism. F1000Res. 2017;6:2134.","journal-title":"F1000Res"},{"key":"741_CR82","doi-asserted-by":"publisher","first-page":"16028","DOI":"10.1038\/celldisc.2016.28","volume":"2","author":"B Titz","year":"2016","unstructured":"Titz B, Lomova A, Le A, Hugo W, Kong X, Ten Hoeve J, Friedman M, Shi H, Moriceau G, Song C, et al. JUN dependency in distinct early and late BRAF inhibition adaptation states of melanoma. Cell Discov. 2016;2:16028.","journal-title":"Cell Discov"},{"key":"741_CR83","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.neo.2016.08.002","volume":"18","author":"M Miyake","year":"2016","unstructured":"Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, Torimoto K, Aoki K, Tanaka N, Shimada K, et al. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia. 2016;18:636\u201346.","journal-title":"Neoplasia"},{"key":"741_CR84","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1038\/onc.2013.191","volume":"33","author":"G Comito","year":"2014","unstructured":"Comito G, Giannoni E, Segura CP, Barcellos-de-Souza P, Raspollini MR, Baroni G, Lanciotti M, Serni S, Chiarugi P. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene. 2014;33:2423\u201331.","journal-title":"Oncogene"},{"key":"741_CR85","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/onc.2014.18","volume":"34","author":"C Rupp","year":"2015","unstructured":"Rupp C, Scherzer M, Rudisch A, Unger C, Haslinger C, Schweifer N, Artaker M, Nivarthi H, Moriggl R, Hengstschlager M, et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. Oncogene. 2015;34:815\u201325.","journal-title":"Oncogene"},{"key":"741_CR86","doi-asserted-by":"publisher","first-page":"16231","DOI":"10.1038\/s41598-017-13431-y","volume":"7","author":"D Zhang","year":"2017","unstructured":"Zhang D, Ding L, Li Y, Ren J, Shi G, Wang Y, Zhao S, Ni Y, Hou Y. Midkine derived from cancer-associated fibroblasts promotes cisplatin-resistance via up-regulation of the expression of lncRNA ANRIL in tumour cells. Sci Rep. 2017;7:16231.","journal-title":"Sci Rep"},{"key":"741_CR87","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1158\/0008-5472.CAN-11-0036","volume":"71","author":"C Gungor","year":"2011","unstructured":"Gungor C, Zander H, Effenberger KE, Vashist YK, Kalinina T, Izbicki JR, Yekebas E, Bockhorn M. Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer. Cancer Res. 2011;71:5009\u201319.","journal-title":"Cancer Res"},{"key":"741_CR88","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fcell.2018.00038","volume":"6","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Kitamura T. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front Cell Dev Biol. 2018;6:38.","journal-title":"Front Cell Dev Biol"},{"key":"741_CR89","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00262-011-1109-0","volume":"61","author":"F Bai","year":"2012","unstructured":"Bai F, Villagra AV, Zou J, Painter JS, Connolly K, Blaskovich MA, Sokol L, Sebti S, Djeu JY, Loughran TP, et al. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. Cancer Immunol Immunother. 2012;61:523\u201333.","journal-title":"Cancer Immunol Immunother"},{"key":"741_CR90","doi-asserted-by":"publisher","first-page":"7617","DOI":"10.4049\/jimmunol.181.11.7617","volume":"181","author":"WN D'Souza","year":"2008","unstructured":"D'Souza WN, Chang CF, Fischer AM, Li M, Hedrick SM. The Erk2 MAPK regulates CD8 T cell proliferation and survival. J Immunol. 2008;181:7617\u201329.","journal-title":"J Immunol"},{"key":"741_CR91","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ejca.2016.09.010","volume":"68","author":"M de Charette","year":"2016","unstructured":"de Charette M, Marabelle A, Houot R. Turning tumour cells into antigen presenting cells: the next step to improve cancer immunotherapy? Eur J Cancer. 2016;68:134\u201347.","journal-title":"Eur J Cancer"},{"key":"741_CR92","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer. 2012;12:237\u201351.","journal-title":"Nat Rev Cancer"},{"key":"741_CR93","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.it.2016.12.007","volume":"38","author":"L Tao","year":"2017","unstructured":"Tao L, Reese TA. Making mouse models that reflect human immune responses. Trends Immunol. 2017;38:181\u201393.","journal-title":"Trends Immunol"},{"key":"741_CR94","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1177\/0192623316675767","volume":"45","author":"RS Sellers","year":"2017","unstructured":"Sellers RS. Translating mouse models. Toxicol Pathol. 2017;45:134\u201345.","journal-title":"Toxicol Pathol"},{"key":"741_CR95","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00005-018-0506-x","volume":"66","author":"KSM Yong","year":"2018","unstructured":"Yong KSM, Her Z, Chen Q. Humanized mice as unique tools for human-specific studies. Arch Immunol Ther Exp. 2018;66:245\u201366.","journal-title":"Arch Immunol Ther Exp"},{"issue":"5","key":"741_CR96","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/cells8050470","volume":"8","author":"Jumpei Kondo","year":"2019","unstructured":"Kondo J, Inoue M. Application of cancer organoid model for drug screening and personalized therapy. Cells. 2019;8(5):470. https:\/\/doi.org\/10.3390\/cells8050470.","journal-title":"Cells"},{"key":"741_CR97","doi-asserted-by":"crossref","unstructured":"Lee HW, Chung W, Lee H-O, Jeong DE, Jo A, Lim JE, Hong JH, Nam D-H, Jeong BC, Park SH, et al: Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient. Study Identifier: EGAD00001005978. https:\/\/identifiers.org\/ega.dataset: EGAD00001005978 Eur Genome-phenome Arch 2020.","DOI":"10.1186\/s13073-020-00741-6"},{"key":"741_CR98","unstructured":"Lee HW, Chung W, Lee H-O, Jeong DE, Jo A, Lim JE, Hong JH, Nam D-H, Jeong BC, Park SH, et al: RNA sequencing of chemotherapy-resistant muscle-invasive urothelial bladder cancer. GEO data series: GSE145140. https:\/\/www.ncbi.nlm.nih.gov\/geo\/query\/acc.cgi?acc=GSE145140 Gene Expression Omnibus 2020.."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-020-00741-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-020-00741-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-020-00741-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T22:55:48Z","timestamp":1666652148000},"score":1,"resource":{"primary":{"URL":"https:\/\/genomemedicine.biomedcentral.com\/articles\/10.1186\/s13073-020-00741-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["741"],"URL":"https:\/\/doi.org\/10.1186\/s13073-020-00741-6","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,27]]},"assertion":[{"value":"11 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local committee on the use of human samples for experimental studies of the Samsung Medical Center (SMC), Seoul, Republic of Korea (IRB file #201004004). Written informed consent was provided by the participant prior to enrollment. All experimental methods abided by the Declaration of Helsinki. All mouse procedures were approved by the IRB at SMC (#20170720002) and carried out in accordance with the National Institute of Health Guidelines for the Care and Use of Laboratory Animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was provided by the participant prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}